NZ747378A - Ultra low density pulmonary powders - Google Patents
Ultra low density pulmonary powdersInfo
- Publication number
- NZ747378A NZ747378A NZ747378A NZ74737813A NZ747378A NZ 747378 A NZ747378 A NZ 747378A NZ 747378 A NZ747378 A NZ 747378A NZ 74737813 A NZ74737813 A NZ 74737813A NZ 747378 A NZ747378 A NZ 747378A
- Authority
- NZ
- New Zealand
- Prior art keywords
- low density
- ultra low
- powders
- pharmaceutical compositions
- pulmonary powders
- Prior art date
Links
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- 239000000843 powder Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing levodopa and having a geometric size of 8 μm to 12 μm, a tap density of 0.25 g/cm3 to 0.050 g/cm3, and a water content between 1.90 and 2.90 weight percent. The invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261724781P | 2012-11-09 | 2012-11-09 | |
| US13/679,245 US8545878B1 (en) | 2012-11-09 | 2012-11-16 | Capsules containing high doses of levodopa for pulmonary use |
| US13/945,160 US8685442B1 (en) | 2012-11-09 | 2013-07-18 | Capsules containing high doses of levodopa for pulmonary use |
| US201361884319P | 2013-09-30 | 2013-09-30 | |
| US201361884436P | 2013-09-30 | 2013-09-30 | |
| US201361884315P | 2013-09-30 | 2013-09-30 | |
| NZ70868313 | 2013-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ747378A true NZ747378A (en) | 2019-06-28 |
Family
ID=67068233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ747378A NZ747378A (en) | 2012-11-09 | 2013-11-08 | Ultra low density pulmonary powders |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ747378A (en) |
-
2013
- 2013-11-08 NZ NZ747378A patent/NZ747378A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005768A (en) | Ultra low density pulmonary powders. | |
| PH12017500778A1 (en) | COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS | |
| MY162391A (en) | Process for preparing carrier particles for dry powders for inhalation | |
| MX354828B (en) | Monovalent metal cation dry powders for inhalation. | |
| IN2014DN07611A (en) | ||
| MX351781B (en) | Inhalable pharmaceutical compositions. | |
| MX2013013440A (en) | Compositions, methods & systems for respiratory delivery of two or more active agents. | |
| EP2571486A4 (en) | Dry powder inhalation composition | |
| EP4316473A3 (en) | Use of stearate in an inhalable formulation | |
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| UA101652C2 (en) | Composition for inhalation comprising aclidinium for the treatment of asthma and chronic obstructive pulmonary disease | |
| GEP20186865B (en) | Dry powder inhaler and inhalation actuated mechanism thereof | |
| PH12014502662A1 (en) | Novel dosage form and formulation of abediterol | |
| MX2022009231A (en) | Dry powder inhaler and methods of use. | |
| EP2682102A3 (en) | Inhalation Compositions Comprising Corticosteroid and Sorbitol | |
| WO2014007781A3 (en) | Inhalation compositions | |
| WO2014007772A3 (en) | Inhalation compositions comprising glucose anhydrous | |
| IN2014DN08421A (en) | ||
| WO2014007771A3 (en) | Inhalation compositions comprising muscarinic receptor antagonist | |
| MX2015009891A (en) | Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy. | |
| UA115989C2 (en) | Dry powder inhaler compositions comprising long acting muscorinic antagonists | |
| MX2015012931A (en) | Micronized pharmaceutical compositions. | |
| NZ747378A (en) | Ultra low density pulmonary powders | |
| EP2866792A4 (en) | Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture | |
| MX2015014338A (en) | A pharmaceutical composition containing budesonide and formoterol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2020 BY CPA GLOBAL Effective date: 20191107 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2021 BY CPA GLOBAL Effective date: 20201022 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2022 BY CPA GLOBAL Effective date: 20210930 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2023 BY CPA GLOBAL Effective date: 20221007 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2024 BY CPA GLOBAL Effective date: 20231102 |